Quizartinib for FLT3-ITD positive AML after second-line chemo or stem cell transplant from flt3 itd mutation positive Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: Research suggests that a new targeted therapy, quizartinib, may be a safe and effective option to treat a subset of patients with treatment-resistant acute myeloid leukaemia (AML), whose leukaemia has the FLT3-ITD mutation.nnQuizartinib is the first and only single-agent drug that has produced a clinical benefit in AML patients with this deadly mutation who have failed previous therapy.nnThe number of patients bridged to a stem cell transplant was very significant. Dr Levis and his colleagues pl